Hypha Discovery is a UK-based biotechnology company that supports pharmaceutical and agrochemical companies by producing metabolites and new derivatives of drugs and pesticides in discovery and development. Hypha is an expert in the scalable synthesis of drug metabolites and oxidised derivatives of lead compounds, and possess a wealth of experience in the production, purification and structure elucidation of natural products.
NEW PolyCYPs® biocatalysis kits
Hypha’s PolyCYPs® kits provide a fast and scalable way to access CYP-derived drug metabolites and derivatives formed by oxidation at aliphatic or aromatic moieties. Download a pdf of the PolyCYPs brochure.
Click here to find out more about PolyCYPs kits
NEWS & EVENTS
Come and meet us at the following events
ACS Fall meeting 2019
25th – 29th August 2019, San Diego, USA
Dr Liam Evans will be giving a talk on “Use of PolyCYPs enzymes for accessing mammalian metabolites of agrochemicals and pharmaceutical drugs” in the morning session of Tuesday 27th August.
20th SCI/RSC Medicinal Chemistry Symposium
8th – 11th September 2019, Cambridge UK
Come and see us at Stand X
Download a copy of our brochure on drug metabolites and C-H activated derivatives
Our brochure on drug metabolites and C-H activated derivatives is now available. Inside we feature interesting case studies and client projects, including the following topics:
- Phase l CYP and non-CYP metabolites
- Phase ll conjugated metabolites such as glucuronides and sulfates
- Isotopically labelled metabolites
- Lead diversification / late stage functionalization
- Production of polar derivatives of drug lead compounds
Let us know if you would like a copy of a new paper published in Xenobiotica entitled Microbial Biotransformation – An Important Tool for the Study of Drug Metabolism, which describes some interesting projects Hypha have undertaken for Merck and Janssen with several difficult-to-synthesise hydroxylated and glucuronidated metabolites. Read the abstract at http://bit.ly/2xb6H9d
In a recent newsletter we look at the use of microbial biotransformation to produce scalable quantities of glucuronides, focussing on the synthesis of acyl glucuronides of carboxylic acid-containing drugs.
Access a pdf of the newsletter on glucuronides of carboxylic acid-containing drugs